Immuno-oncology therapies have the potential to revolutionize the armamentarium of available cancer treatments. To further improve clinical response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment. This Review highlights the significance of small molecules in this approach, which holds promise to provide increased benefit to cancer patients.
Keywords: T-cells; checkpoint inhibitor; combination therapy; kinase inhibitors; small molecules.
© 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.